Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-cash Items (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-cash Items for 7 consecutive years, with $51.6 million as the latest value for Q4 2024.

  • Quarterly Non-cash Items rose 88.91% to $51.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $51.6 million through Dec 2024, up 88.91% year-over-year, with the annual reading at $51.6 million for FY2024, 88.91% up from the prior year.
  • Non-cash Items for Q4 2024 was $51.6 million at Rhythm Pharmaceuticals, up from $27.3 million in the prior quarter.
  • The five-year high for Non-cash Items was $74.0 million in Q4 2022, with the low at $3.2 million in Q4 2021.
  • Average Non-cash Items over 4 years is $39.0 million, with a median of $39.5 million recorded in 2023.
  • The sharpest move saw Non-cash Items surged 2202.24% in 2022, then plummeted 63.08% in 2023.
  • Over 4 years, Non-cash Items stood at $3.2 million in 2021, then soared by 2202.24% to $74.0 million in 2022, then crashed by 63.08% to $27.3 million in 2023, then surged by 88.91% to $51.6 million in 2024.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $51.6 million, $27.3 million, and $74.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.